50 /100
MEDIUM RISK
Score updated Jul 14, 2026

SER — Serina Therapeutics, Inc. Dilution Risk Tracker

Track SER dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SER — Get alerts when the score changes →

As of July 14, 2026, Serina Therapeutics, Inc. (SER) has a DilutionWatch DilutionScore of 50/100, rated MEDIUM dilution risk. Serina Therapeutics, Inc. has a market capitalization of $27.60M, 15.00M shares outstanding, 25 institutional holders tracked. Key dilution vectors include 54.0K outstanding warrants, approximately 24 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
25
📊 Float Risk
55
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
29%
🔁 Convertible Conversion 40%
• Significant convertible debt: 18% potential dilution
• Elevated convertible risk (60/100)
🔄 Reverse Split 30%
• 50-day avg $1.98 approaching $1 threshold
🔔 Track SER — Get forecast alerts →

💹 Market Data

Market Cap$27.60M
Shares Outstanding15.00M
Float8.42M
Cash$24.53M
Debt$11.15M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 259.7% shares (2026Q1 vs prior)
25 institutional holders · 1.61M shares
#1 Sio Capital Management, LLC 1.00M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 318.3K shares
#3 Waverly Advisors, LLC 67.5K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest285.4K
Days to Cover3.5
% of Float3.4%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2025
Form 4 INSIDER TRANSACTION Mar 23, 2026
Form 4 INSIDER TRANSACTION Mar 19, 2026
Form 4 INSIDER TRANSACTION Feb 02, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for SER Shareholders

Serina Therapeutics, Inc. (SER) has a DilutionScore of 50/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for SER shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for SER in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for SER alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track SER Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking SER — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for SER
📊 SER FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 SER Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.